Skip to main content
OpenTrials
Completed

NCT Number: NCT07420179

Derivo 2 Heal vs Derivo 2: In-Stent Stenosis After Flow Diversion

The goal of this clinical trial is to learn whether a coated flow diverter leads to fewer in-stent narrowings (in-stent stenosis) than an otherwise identical uncoated flow diverter when used to treat intracranial aneurysms in routine clinical care. The main questions it aims to answer are:

Does the coated flow diverter reduce the rate and severity of in-stent stenosis compared with the uncoated flow diverter?

Are there differences in angiographic aneurysm occlusion and procedure-related complications between the two devices?

Researchers will compare treatment with the coated flow diverter (Derivo 2 heal) to the uncoated flow diverter (Derivo 2).

Participants will:

Receive endovascular treatment of their intracranial aneurysm with one of the two flow diverters assigned by randomization

Receive standard antiplatelet medication and follow-up imaging as part of routine care

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Saarland University Hospital

Homburg, Saarland, 66421, Germany

About this study

This investigator-initiated, prospective, single-center randomized clinical study compared a surface-modified flow diverter (Derivo 2 heal; Acandis, Germany) with the corresponding uncoated device (Derivo 2) in the endovascular treatment of unruptured saccular internal carotid artery (ICA) aneurysms in routine clinical care. After confirmation of eligibility and written informed consent, patients were randomized in a 1:1 ratio to receive either the coated or uncoated flow diverter using a computer-generated permuted block randomization scheme with variable block sizes. Allocation concealment was ensured using sequentially numbered, opaque, sealed envelopes prepared by an independent study coordinator. Device diameter and length were selected according to a predefined institutional sizing standard based on angiographic measurements, independent of treatment allocation.

All procedures were performed under general anesthesia via a transfemoral approach using standard technique. No adjunctive coiling and no balloon angioplasty were performed. All participants received dual antiplatelet therapy with aspirin 100 mg/day and clopidogrel 75 mg/day initiated at least 3 days before the procedure and continued for at least 12 months; platelet function testing was not routinely performed.

Angiographic follow-up was scheduled at 3 and 9 months using digital subtraction angiography (DSA). In-stent stenosis (ISS) was defined as a segmental reduction of the contrast-filled parent vessel lumen within the stented segment compared with the immediate post-procedural angiogram. Because absolute calibration is limited in 2D projection imaging, ISS severity was assessed using a standardized ratio-based approach: the vessel diameter at the site of maximal stenosis was related to a reference segment in the petrous ICA, and the resulting ratio was compared with the corresponding ratio on the immediate post-procedural angiogram to quantify relative luminal narrowing over time. For descriptive purposes, high-grade ISS (>50%) was recorded. In addition, ISS was morphologically categorized as stenosis associated with visible stent deformation (e.g., focal flattening, incomplete expansion, segmental collapse, fish-mouth configuration) versus stenosis without visible deformation, the latter interpreted as predominantly related to intimal hyperplasia.

Aneurysm occlusion was assessed on follow-up DSA using the O'Kelly-Marotta (OKM) grading scale. Complete occlusion was predefined as OKM grade D (no residual aneurysm filling). Clinical events and adverse events were prospectively recorded during the periprocedural period and follow-up visits.

The primary objective was to compare the incidence and severity of ISS between the coated and uncoated flow diverter groups over time. Secondary objectives included comparison of aneurysm occlusion rates and evaluation of relationships between angiographic outcomes and device- or vessel-related factors.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged ≥18 years
  • Unruptured, saccular aneurysm of the internal carotid artery (ICA) suitable for single-device flow diverter treatment
  • Availability of angiographic follow-up imaging at both 3 and 9 months

Exclusion criteria

  • Fusiform or dissecting aneurysms
  • Requirement for multiple flow diverter implantation
  • Previous treatment of the target aneurysm
  • Contraindications to dual antiplatelet therapy

Treatment and study plan

Coated Flow Diverter

Device

A surface-modified intracranial flow diverter stent with an anti-thrombogenic coating (Derivo 2 heal, Acandis, Germany) used for endovascular treatment of unruptured intracranial internal carotid artery aneurysms. Device diameter and length are selected individually based on angiographic measurements according to institutional routine practice.

Uncoated Flow Diverter

Device

The corresponding uncoated intracranial flow diverter stent (Derivo 2, Acandis, Germany) used for endovascular treatment of unruptured intracranial internal carotid artery aneurysms. Device diameter and length are selected individually based on angiographic measurements according to institutional routine practice.

Primary outcomes

  1. In-Stent Stenosis Severity (Ratio-Based Luminal Narrowing)

    Time frame: 3 months and 9 months after the procedure (DSA follow-up)

    In-stent stenosis (ISS) quantified on follow-up digital subtraction angiography (DSA) using a standardized ratio-based approach: the diameter at maximal stenosis within the stented segment relative to a reference segment (petrous ICA), compared with the corresponding ratio on the immediate post-procedural angiogram to derive relative luminal narrowing over time. Higher values indicate greater luminal narrowing (ISS severity).

Secondary outcomes

  1. High-Grade In-Stent Stenosis (>50%)

    Time frame: 3 months and 9 months after the procedure

    Proportion of participants with high-grade in-stent stenosis defined as >50% luminal narrowing within the stented segment on follow-up DSA.

  2. Complete Aneurysm Occlusion (OKM Grade D)

    Time frame: 3 months and 9 months after the procedure

    Complete angiographic occlusion on follow-up DSA defined as O'Kelly-Marotta (OKM) grade D (no residual aneurysm filling).

  3. Procedure-Related Complications

    Time frame: Periprocedural period through 9 months

    Occurrence of periprocedural complications related to the endovascular treatment (e.g., thromboembolic events, hemorrhagic complications, device-related adverse events) recorded prospectively.

Sponsors and collaborators

Lead sponsor

Universität des Saarlandes

Other

Registry information

Official study title

Derivo-ISS: A Prospective Randomized Study Comparing In-Stent Stenosis After Treatment With a Coated Versus Uncoated Flow Diverter (Derivo 2 Heal vs Derivo 2) for Intracranial ICA Aneurysms

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
Feb 19, 2026
Registry last updated
Feb 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.